



Kimia Biosciences Limited

Regd. Office/Works : Village-Bhondsi, Tehsil-Sohna, Distt. Gurugram (Haryana)
E-mail : compliance.kimia@gmail.com & info@kimiabiosciences.com
Web : www.kimiabiosciences.com | CIN NO. : L24239HR1993PLC032120
Tel. : +91 9654746544, 9654206544

Ref : KIMIABL/COMP/BSE/21-22/019

AUGUST 12, 2021

To

**Department of Corporate Affairs- Listing
BSE Limited**

PhirozJeeJeebhoy Towers,
Dalal Street, Fort Mumbai-400001

Scrip Code: 530313 [KIMIABL]

ISIN: INE285U01025

Sub: Outcome of Board Meeting held on Thursday, August 12, 2021

Dear Sir,

Pursuant to Regulation 33 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company in their meeting held today i.e. Thursday, August 12, 2021, has inter-alia considered and approved:

1. Unaudited Financial Results for the first quarter ended June 30, 2021
2. Limited Review Report on the aforesaid results from Statutory Auditors of the Company
3. Constitution of Corporate Social Responsibility Committee ("CSR Committee") pursuant to applicability of section 135 of the Companies Act, 2013. Composition of the committee is given below:

Composition of CSR Committee		
Sr. No.	Name of Director	Designation
1.	Mr. Sameer Goel	Chairman (Executive Managing Director)
2.	Mr. Jagdeep Dhawan	Member (Independent Director)
3.	Mr. Vipul Goel	Member (Non Executive Director)

The Board Meeting commenced at 03:00 p.m. and concluded at 04:00 p.m.
Kindly take the above information on your records.

Thanking You,
Yours faithfully,

For **Kimia Biosciences Limited**


Abhishek Kumar Pandey
(Company Secretary & Compliance Officer)
PLACE: New Delhi



Encl.: A/a.

Independent Auditor's Review Report on Unaudited Financial Results for the quarter ended June 30, 2021 Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as amended

To the Board of Directors of Kimia Bioscience Limited

1. We have reviewed the accompanying statement of unaudited financial results ("the Statement") of Kimia Bioscience Limited ("the Company") for the quarter ended June 30, 2021. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results read with notes therein, prepared in all material respects in accordance with the applicable accounting standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Place: Noida (Delhi – NCR)
Date: August 12, 2021

For Singhi & Co.
Chartered Accountants
Firm Registration No. 302049E

sp
Bimal Kumar Sipani
Partner

Membership No. 088926
UDIN : 21088926AAAAALM6342

KIMIA BIOSCIENCES LIMITED

Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102

Phone: +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com & info@kimiabiosciences.com

Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2021

(₹ Lakhs except EPS)

S. No.	Particulars	Quarter ended			Year ended
		30-06-2021	31-03-2021	30-06-2020	31-03-2021
		(Unaudited)	(Audited) (refer note 3)	(Unaudited)	(Audited)
I	Revenue from Operations	3,086.91	3,601.33	2,485.03	13,271.38
II	Other Income	17.39	47.10	37.10	245.62
III	Total Income (I+II)	3,104.30	3,648.43	2,522.13	13,517.00
IV	Expenses:				
a)	Cost of materials consumed	2,082.20	2,924.25	2,559.42	10,312.59
b)	Purchase of stock-in-trade	-	-	-	-
c)	Change in inventories of finished goods and work-in-progress	50.21	(99.28)	(911.90)	(627.22)
d)	Employee benefits expenses	365.20	378.62	291.91	1,409.10
e)	Finance costs	78.23	100.71	69.87	339.00
f)	Depreciation and amortisation expense	65.21	59.62	40.41	191.06
g)	Other expenses	419.35	405.94	274.89	1,339.03
V	Total Expenses (IV)	3,060.40	3,769.86	2,324.60	12,963.56
VI	Profit/(loss) before exceptional items and Tax (III-V)	43.90	(121.43)	197.53	553.44
VII	Exceptional Items	-	-	-	-
VIII	Profit/(loss) Before Tax (VI-VII)	43.90	(121.43)	197.53	553.44
IX	Tax expenses:				
a)	Current Tax	-	(4.50)	-	-
b)	Deferred Tax charge / (reversal)	12.12	(26.31)	-	43.00
X	Profit/(loss) for the period (VII-IX)	31.78	(90.62)	197.53	510.44
XI	Other Comprehensive Income				
A.	Items that will not be reclassified to Profit or Loss (Net of Tax)				
-	Remeasurement of defined benefit plans	-	-	-	(3.99)
B.	Items that will be reclassified to Profit or Loss (Net of Tax)	-	-	-	-
XII	Total Comprehensive Income for the period (X+XI)	31.78	(90.62)	197.53	506.45
XIII	Paid up equity share capital (Face value of Rs.1 per equity share)	473.13	473.13	473.13	473.13
XIV	Other Equity				1,370.52
XV	Earnings per equity share (not annualised)				
	Basic in Rs.	0.07	(0.19)	0.43	1.08
	Diluted in Rs.	0.07	(0.19)	0.43	1.08

- The business activity of the Company falls within a single primary business segment viz 'Pharmaceuticals' and hence there is no other reportable segment as per Ind AS 108 'operating segments'.
- COVID - 19 pandemic has caused disruption on the global economic and business environment. There is uncertainty with regard to its impact which cannot be reasonably determined at this stage. However, the Company has evaluated and considered to the extent possible the likely impact that may arise from COVID-19 pandemic as well as all event and circumstances upto the date of approval of these financial results on the carrying value of its assets and liabilities as at June 30, 2021. Based on the current indicators of future economic conditions, the Company estimates to recover the carrying amount of its assets and has adequate liquidity to discharge its obligations. These estimates are subject to uncertainty and may be affected by the severity and duration of the pandemic. The Company is continuously monitoring any material changes in future economic conditions.
- The figures for the quarter ended March 31, 2021 are the balancing figures between audited figures for the full financial figures and the published year to date figures for the nine months.
- The figures for the previous periods have been regrouped/ rearranged, wherever considered necessary, to confirm current period classifications.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 12.08.2021

 Date : August 12, 2021
 Place : New Delhi


FOR KIMIA BIOSCIENCES LIMITED

Sameer Goel
 Sameer Goel
 Chairman & Managing Director
 DIN - 00161786